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844 Abstracts September 2013of n-3 fatty acids in patients with previous myocardial infarction or heart
failure. The authors suggest primary beneﬁt of n-3 fatty acids is antiar-
rhythmic in patients, such as those with previous myocardial infarction or
heart failure, who are perhaps more prone to ventricular arrhythmic events.
Malignant Emboli on Transcranial Doppler During Carotid Stenting
Predict Postprocedure Diffusion-Weighted Imaging Lesions
Almekhlaﬁ M.A., Demchuk A.M., Mishra S., et al. Stroke 2013;44:1317-
22.
Conclusion: There is a high incidence of embolic signals during
carotid artery stenting, especially when devices are deployed. Malignant
macroemboli predict new images on diffusion-weighted magnetic resonance
imaging (MRI).
Summary: It is now clear that carotid angioplasty and stenting (CAS)
procedures have an increased risk of periprocedural stroke compared with
endarterectomy (Yavin D et al, Can J Neurol Sci 2011;38:230-5). Up to
50% of patients undergoing CAS will have new ischemic lesions on MRI
of the brain after the procedure (Bonati LH et al, Lancet Neurol
2010;9:353-62). The authors postulate that investigating the relative safety
of each step of CAS may help guide improvements in the procedure to lower
the periprocedural stroke rate. They therefore investigated the relative safety
of the steps of CAS by performing intraprocedural transcranial Doppler
(TCD) monitoring and correlating TCD ﬁndings with diffusion-weighted
MRI after the procedure. This was a prospective study in which TCD moni-
toring was performed during CAS procedures. For purposes of the study,
CAS was divided into 11 procedural steps. Embolic signals on TCD were
counted and classiﬁed based on the relative energy index of microembolic
signals as microemboli of one or less or malignant macroemboli as more
than one. All patients had poststenting MRI. The predictive value of
TCD-detected emboli for new diffusion-weighted imaging (DWI) lesions
was evaluated with a negative binomial regression model. The study
enrolled 30 patients, and seven were asymptomatic. The median embolic
signal count was 212.5 (108 microemboli and 80 malignant macroemboli).
The highest median embolic signals occurred during stent deployment, with
a signal count of 58. This was followed by protection device deployment
with a signal count of 30 (P ¼ .0006). Twenty-four patients (80%) had
new DWI lesions on post-CAS MRI. The median DWI count was four
(interquartile range, seven). Two patients (6.7%) had new or worsening
clinical deﬁcits post-CAS. For every malignant embolus, the expected count
of DWI lesions increased by 1% (95% conﬁdence interval, 0%-2%; P ¼ .032).
Comment: It is not surprising that deploying the protection device
and deploying the stent would be associated with the greatest number of
TCD-detected emboli. Fig 2 of the article, however, indicates that all phases
of CAS are associated with TCD-detected microemboli and malignant mac-
roemboli. Although it is true that identifying particular procedural steps that
contribute to improving the adverse event rates of CAS may be important in
improving the procedure, it is also possible CAS is a failed concept for most
patients and should be relegated to very speciﬁc and highly individualized
clinical indications.
Outcomes of Carotid Endarterectomy in the Elderly: Report From the
National Cardiovascular Data Registry
Rajamani K., Kennedy K.F., Ruggiero N.J., et al. Stroke 2013;44:1172-4.
Conclusion: For patients undergoing carotid endarterectomy (CEA),
those aged >85 years are at increased risk for death or perioperative compli-
cations of stroke, death, and myocardial infarction (MI) compared with
younger patients.
Summary: There are case series of CEA that suggest the perioperative
risk in elderly patients is comparable with that in younger patients (Durward
QJ et al, Arch Surg 2005;140:625-8). However, administrative databases
and systemic reviews have suggested CEA in the elderly patient has
increased perioperative morbidity and mortality (Wennberg DE et al,
JAMA 1998;279:1278-81 and Bond R et al, Cerebrovasc Dis
2005;20:69-77). In this paper, the authors, who all appear to be cardi-
ology-based or have connections with the carotid stent industry, report
the result of the CARE registry with respect to CEA in older patients.
The CARE registry is a voluntary, hospital-based, prospective, clinical
procedures registry (https://www.ncdr.com/webncdr/care/; White CJ
et al, Catheter Cardiovasc Interv 2008;71:721-5). The authors believe
that analysis of data from the CARE registry helps to determine “real-
world” outcomes of CEA in the elderly. This was a retrospective cohort
study of patients aged >70 years. Outcomes were stratiﬁed by age and
symptomatic and asymptomatic status. The registry includes data from
171 hospitals, and 4149 patients underwent CEA, 33.1% of whom were
symptomatic. Overall mortality rate was 0.5%. The primary outcome
measure of in-hospital death, stroke, and myocardial infarction was highest
in the group aged >85 years (5.6%). Among symptomatic patients,mortality and the primary outcome were not statistically different between
those aged >75 years and those aged 70 to 74 years. Among asymptomatic
elderly patients, the mortality rate was higher in aged patients >75 years
than in those <75 years (0.7% vs 0.0%, P ¼ .006). However, the combined
outcome of stroke, death, and myocardial infarction was not statistically
different.
Comment: It is a little hard to know what to make of these data.
There were 4149 patients analyzed from January 2005 to March 2011,
purportedly from 171 hospitals. This roughly equates to w25 CEAs, on
average, from each hospital. Over 6 years, this would be less than ﬁve
CEAs per year in each of these hospitals in patients aged >70 years. Either
a lot of potential data are not being analyzed or these are very low-volume
CEA hospitals. Therefore, although enough numbers are here to do statis-
tical analysis, it is very unclear whether the patients analyzed are truly repre-
sentative of those undergoing CEA across the United States. Nevertheless,
likely at the disappointment of the authors, the overall perioperative risk of
complications after CEA in the elderly analyzed within this registry was still
within guidelines for CEA.
Prevalence of Stenoses and Occlusions of Brain-Supplying Arteries in
Young Stroke Patients
von Sarnowski B., Schminke U., Tatlisumak T., et al. Neurology 2013;80:
1287-94.
Conclusion: One-ﬁfth of young patients with stroke have asymptom-
atic or symptomatic large-artery atherosclerosis.
Summary: Signiﬁcant extracranial atherosclerotic carotid stenosis and
occlusions in adult stroke patients of all ages (21-94 years old) occur in 11%
to 22% (Bogousslavsky J et al, Stroke 1988;19:1083-92 and Wasay M et al,
Stroke 2009;40:708-12). However, in younger patients with stroke, athero-
sclerotic changes in the extracranial and large intracranial arteries have not
been considered a major etiology of stroke. Only two previous studies
have reported the prevalence of atherosclerotic stenosis in young stroke
patients, with prevalence of stenosis ranging from 8% to 13% and a 3% prev-
alence of occlusions in transient ischemic attack (TIA) and ischemic stroke in
patients aged<45 years (Carolei A et al, BMJ 1995;310:1363-6 and Lee TH
et al. Stroke 2002;33:1950-5). The authors here aimed to assess the preva-
lence of extracranial and intracranial atherosclerotic stenotic lesions and
occlusions in TIA and ischemic stroke patients aged 18 to 55 years in the
large European, multicenter database of the Stroke in Young Fabry Patients
(Sifap1) study. Sifap1 is a Pan-European multicenter study conducted in 47
centers in 15 countries. The study is primarily designed to investigate the
prevalence of Fabry disease. The current study is a secondary analysis of Sifap
1 data. From the Sifap 1 cohort (n ¼ 5023), the authors analyzed a subset of
patients with complete data from carotid ultrasound studies. Patients with
arterial dissections, vasculitis, and mobile thrombi were excluded. Among
the remaining 2187 patients (1319 men; 744 aged 18-44 years), intracranial
arteries were additionally examined with ultrasound imaging in 1612
patients (73.7%). Patients were stratiﬁed by sex and age groups (younger:
18-44 years; middle-aged: 45-55 years). In patients with ischemic stroke,
overall prevalence of carotid artery stenosis and occlusions was 8.9%
(younger: 4.9%; middle-aged: 11.0%), of which 81% were symptomatic.
Nonstenotic carotid plaques were more common in men than in women
(15.8% vs 7.7%; P < .001) and in middle-aged rather than in younger
patients (17.0% vs 4.9%; P< .001). Supratentorial intracranial artery stenosis
and occlusions amounted to 11.8%. Supratentorial stenosis occurred more
frequently in middle-aged patients (13.0% vs 7.8%; P< .001), whereas occlu-
sions were equally common (both 3.2%; not signiﬁcant).
Comment: The study did not include a control population without
TIA or stroke. The cross-sectional study design does not allow assessment
of the role of progressive atherosclerotic stenosis in the etiology of stroke
in young patients. The study does, however, indicate a high burden of
subclinical atherosclerosis in middle-aged TIA and stroke patients. Of
ischemic stroke patients aged 45 to 55 years, 17% have a detectible carotid
plaque. The study also indicates that intracranial stenosis occurs with reason-
able frequency in young patients with stroke. This suggests that in addition
to carotid duplex scanning to access for cervical carotid lesions, imaging of
intracranial arteries should also be considered in the young stroke patient.
Risk Factors for Early Failure of Surgical Amputations: An Analysis of
8,878 Isolated Lower Extremity Amputation Procedures
O’Brien P.J., Cox M.W., Shortell C.K., et al. J Am Col Surg 2013;216:
836-44.
Conclusion: The risk of early amputation failure can be decreased by
increased operative times and heightened supervision of participating
surgical trainees.
Summary: Nearly 100,000 lower extremity amputation procedures
are performed in the United States each year for complications of critical
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Many amputations fail, and the authors sought to use the American College
of Surgeons (ACS) National Surgical Quality Improvement Program
(NSQIP) database to gather information on predictors and incidence of
early amputation failure. Patients from 2005 to 2010 in the ACS NSQIP
database who underwent isolated lower extremity amputation were included
for analysis. Patients who had a previous operation #30 days, patients
undergoing an open amputation, and patients undergoing another proce-
dure during amputation were excluded from analysis. Predictors of early
amputation failure were determined with multivariate logistic regression
analysis. Early amputation failure was deﬁned as a need for a reoperation
#30 days postoperatively. Data were adjusted for preoperative and intrao-
perative variables. The analysis included 8878 patients who underwent
4258 below-knee amputations (BKA), 3415 above-knee amputations
(AKA), and 1205 transmetatarsal amputations (TMA). The overall rate of
early amputation failure was 12.7%. The rate was 12.6% for BKA, 8.1%
for AKA, and 26.4% for TMA (P < .0001). Preoperative and intraoperative
variables that were independently associated with early amputation failure
included emergency operation, TMA (reference, BKA), sepsis (reference,
no sepsis), septic shock (reference, no sepsis), end-stage renal disease,
systemic inﬂammatory response syndrome (reference, no sepsis), intraoper-
ative surgical trainee participation, body mass index $30 kg/m2, and
continued tobacco use. Characteristics associated with decreased early
amputation failure included age $80 years (reference, <65 years), regional
anesthesia, AKA (reference, BKA), and operative times of 40 to 59 minutes
(reference, <40 minutes), >80 minutes (reference, <40 minutes), and 60
to 79 minutes (reference, <40 minutes).
Comment: These data suggest there are potentially modiﬁable risk
factors for amputation failure. Use of regional rather than general anesthesia
may improve amputation failure rates, spending a bit more time on metic-
ulous surgical technique (ie, a longer operation), and enhanced supervision
of surgical trainees during the performance of the procedure all could
potentially contribute to lower rates of lower extremity amputation failure.
These all seem to be reasonable and relatively easily implemented
suggestions.
Vorapaxar in Patients With Peripheral Artery Disease: Results from
TRA2P-TIMI 50
Bonaca M.P., Scirica B.M., Craeger M.A., et al. Circulation
2013;127:1522-9.
Conclusion: Vorapaxar does not decrease the risk of cardiovascular
death, stroke, or myocardial infarction in patients with peripheral artery
disease (PAD). It does result in reduced limb ischemia and reduced periph-eral revascularization. The beneﬁts on limb vascular events were accompa-
nied by an increased risk of bleeding.
Summary: Vorapaxar is an antagonist of protease-activated receptor-
1, a primary receptor for thrombin on human platelets present on vascular
endothelial and smooth muscle. Patients with PAD are at increased risk of
acute atherothrombotic events complicating atherosclerosis. This includes
myocardial infarction, stroke, and cardiovascular death. Antiplatelet therapy
appears to reduce the risk of cardiovascular events in patients with PAD
(Antithrombotic Trialists’ Collaboration, BMJ 2002;324:71-86). The Pre-
venting Heart Attack and Stroke in Patients with Atherosclerosis
(TRA2P-TIMI 50) trial evaluated the safety and efﬁcacy of vorapaxar
for secondary prevention in patients with established atherosclerosis that
was manifested as prior myocardial infarction, PAD, or ischemic stroke.
Vorapaxar resulted in an overall 13% reduction in major cardiovascular
events (P < .001; Morrow DA et al, Am Heart J 2009;158:335-41.e3).
In this current analysis, investigators focused on the effect of vorapaxar
on peripheral vascular and cardiovascular outcomes in patients qualiﬁed
for TRA2P-TIMI 50 with symptomatic PAD. This was a randomized,
double-blind, placebo-controlled trial of vorapaxar in 26,449 patients
with stable atherosclerotic vascular disease. Patients had PAD as a qualifying
criteria if they had a history of claudication and an ankle-brachial index of
<0.85 or prior revascularization for limb ischemia. There were 3787 such
patients. The primary efﬁcacy end points were cardiovascular death,
myocardial infarction, or stroke, and the principal safety end point was
bleeding. In the PAD cohort, the primary end point did not differ signif-
icantly with vorapaxar (11.3% vs 11.9%; hazard ratio [HR], 0.94; 95%
conﬁdence interval [CI], 0.78-1.14; P ¼ .53). However, rates of hospital-
ization for acute limb ischemia (2.3% vs 3.9%; HR, 0.58; 95% CI, 0.39-
0.86; P ¼ .006) and peripheral artery revascularization (18.4% vs 22.2%;
HR, 0.84; 95% CI, .073-0.97; P ¼ .017) were lower in patients random-
ized to vorapaxar. Bleeding occurred more frequently in patients random-
ized to vorapaxar than to placebo (7.4% vs 4.5%; HR, 1.62; 95% CI, 1.21-
2.18; P ¼ .001).
Comment: Vorapaxar is a novel new antiplatelet agent. It is disap-
pointing the primary efﬁcacy end point of cardiovascular death, myocardial
infarction, or stroke was not achieved in the study. A somewhat surprising
ﬁnding, however, was that the drug signiﬁcantly reduced hospitalization
for acute limb ischemia and peripheral revascularization. This suggests
a potential therapeutic application in patients at high risk for acute limb
ischemic events. Despite the increased risk of bleeding, the drug may have
clinical efﬁcacy in patients at high risk for peripheral vascular events such
as those with previous bypass grafts, angioplasty, or low ankle-brachial
indices. This will need to be studied in a population of patients reﬂective
of these parameters.
